MSD and Daiichi Sankyo started enrolling patients into the phase 3 Ideate-Lung02 study in the summer.

The Missouri case was detected through routine flu season surveillance, said the CDC, and is also the first time that an H5 ...

The headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa ...

Now, in a stunning reversal, Advanz has won a reprieve after the General Court of the European Union ordered a suspension of ...

The agreement ties in with Lilly's strategy of making genetic medicines targeting DNA and RNA a key pillar of its R&D, ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), ...

AstraZeneca has confirmed that some of its current and former employees have been taken into custody in China as part of an ...

Pay a tax of up to 1,900% (not 95%) on the total sales revenue of the medicine selected for price setting. News coverage ...

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies ...

The CEO's departure comes after Lykos co-founder and longtime psychedelic medicines advocate Rick Doblin stood down from the ...

The company recently claimed FDA approval for the first description DTx for major depressive disorder (MDD) – ...